Tinzaparin is a medication used in this clinical trial to prevent blood clots in patients with metastatic colorectal cancer. It is a type of low molecular weight heparin (LMWH) that helps reduce the risk of venous thromboembolic events, which are blood clots that can occur in the veins. The trial aims to assess the effectiveness of using tinzaparin for four months to prevent these clots in patients starting their first line of cancer treatment.

Stage IV Colon or Rectal Adenocarcinoma – This is an advanced form of cancer that originates in the colon or rectum and has spread to other parts of the body. It typically begins as a growth called a polyp on the inner lining of the colon or rectum, which can become cancerous over time. In stage IV, the cancer has metastasized, meaning it has spread beyond the original site to distant organs such as the liver or lungs. Symptoms may include changes in bowel habits, blood in the stool, abdominal pain, and unexplained weight loss. The progression of the disease can vary, with some patients experiencing rapid spread while others may have a slower progression. Management focuses on controlling the spread and alleviating symptoms.

Venous Thromboembolism (VTE) – This condition involves the formation of blood clots in the veins, which can lead to serious complications if not managed. It includes deep vein thrombosis (DVT), where clots form in deep veins, usually in the legs, and pulmonary embolism (PE), where a clot travels to the lungs. Symptoms of DVT may include swelling, pain, and redness in the affected limb, while PE can cause shortness of breath, chest pain, and coughing. VTE can occur incidentally or be symptomatic, and it may be associated with certain risk factors such as cancer, surgery, or prolonged immobility. The condition can progress if clots dislodge and travel to vital organs, necessitating careful monitoring and management.